234 related articles for article (PubMed ID: 34571876)
1. Immune Checkpoint Inhibitors in People Living with HIV/AIDS: Facts and Controversies.
Castelli V; Lombardi A; Palomba E; Bozzi G; Ungaro R; Alagna L; Mangioni D; Muscatello A; Bandera A; Gori A
Cells; 2021 Aug; 10(9):. PubMed ID: 34571876
[TBL] [Abstract][Full Text] [Related]
2. Immune checkpoint inhibitors as potential therapy for reverting T-cell exhaustion and reverting HIV latency in people living with HIV.
Benito JM; Restrepo C; García-Foncillas J; Rallón N
Front Immunol; 2023; 14():1270881. PubMed ID: 38130714
[TBL] [Abstract][Full Text] [Related]
3. Key considerations and common adverse events for HIV-positive patients with cancer treated with immune checkpoint inhibitors.
Yekedüz E; Utkan G; Ürün Y
Future Oncol; 2022 Feb; 18(4):413-416. PubMed ID: 35018793
[TBL] [Abstract][Full Text] [Related]
4. Immune Checkpoint Inhibitors and Infection: What Is the Interplay?
Papadakis M; Karniadakis I; Mazonakis N; Akinosoglou K; Tsioutis C; Spernovasilis N
In Vivo; 2023; 37(6):2409-2420. PubMed ID: 37905657
[TBL] [Abstract][Full Text] [Related]
5. Safety and Efficacy of Immune Checkpoint Inhibitor Therapy in Patients With HIV Infection and Advanced-Stage Cancer: A Systematic Review.
Cook MR; Kim C
JAMA Oncol; 2019 Jul; 5(7):1049-1054. PubMed ID: 30730549
[TBL] [Abstract][Full Text] [Related]
6. Immune checkpoint inhibitor therapy for cancer patients infected with HIV: A systematic review.
Luo L; Xu Y; Li T
Asia Pac J Clin Oncol; 2022 Apr; 18(2):e17-e22. PubMed ID: 32506823
[TBL] [Abstract][Full Text] [Related]
7. Immune checkpoint inhibitors: a promising anticancer therapy.
Singh S; Hassan D; Aldawsari HM; Molugulu N; Shukla R; Kesharwani P
Drug Discov Today; 2020 Jan; 25(1):223-229. PubMed ID: 31738877
[TBL] [Abstract][Full Text] [Related]
8. Immune checkpoint blockade in HIV.
Gubser C; Chiu C; Lewin SR; Rasmussen TA
EBioMedicine; 2022 Feb; 76():103840. PubMed ID: 35123267
[TBL] [Abstract][Full Text] [Related]
9. Reversal of the CD8
Li J; Huang HH; Tu B; Zhou MJ; Hu W; Fu YL; Li XY; Yang T; Song JW; Fan X; Jiao YM; Xu RN; Zhang JY; Zhou CB; Yuan JH; Zhen C; Shi M; Wang FS; Zhang C
Front Immunol; 2021; 12():687296. PubMed ID: 34177939
[TBL] [Abstract][Full Text] [Related]
10. Remembering the forgotten child: the role of immune checkpoint inhibition in patients with human immunod eficiency virus and cancer.
Adashek JJ; Junior PNA; Galanina N; Kurzrock R
J Immunother Cancer; 2019 May; 7(1):130. PubMed ID: 31113482
[TBL] [Abstract][Full Text] [Related]
11. Synergistic potential of immune checkpoint inhibitors and therapeutic cancer vaccines.
Oladejo M; Paulishak W; Wood L
Semin Cancer Biol; 2023 Jan; 88():81-95. PubMed ID: 36526110
[TBL] [Abstract][Full Text] [Related]
12. Tumor immunotherapies by immune checkpoint inhibitors (ICIs); the pros and cons.
Naimi A; Mohammed RN; Raji A; Chupradit S; Yumashev AV; Suksatan W; Shalaby MN; Thangavelu L; Kamrava S; Shomali N; Sohrabi AD; Adili A; Noroozi-Aghideh A; Razeghian E
Cell Commun Signal; 2022 Apr; 20(1):44. PubMed ID: 35392976
[TBL] [Abstract][Full Text] [Related]
13. Mechanisms of resistance to immune checkpoint inhibitors.
Nagasaki J; Ishino T; Togashi Y
Cancer Sci; 2022 Oct; 113(10):3303-3312. PubMed ID: 35848888
[TBL] [Abstract][Full Text] [Related]
14. Managing viral hepatitis in cancer patients under immune checkpoint inhibitors: should we take the risk?
De Keukeleire SJ; Vermassen T; Nezhad ZM; Kerre T; Kruse V; Vlierberghe HV; Vermaelen K; Rottey S
Immunotherapy; 2021 Apr; 13(5):409-418. PubMed ID: 33487052
[TBL] [Abstract][Full Text] [Related]
15. Pleiotropic Effects of Metformin on the Antitumor Efficiency of Immune Checkpoint Inhibitors.
Liu W; Wang Y; Luo J; Liu M; Luo Z
Front Immunol; 2020; 11():586760. PubMed ID: 33603734
[TBL] [Abstract][Full Text] [Related]
16. miRNAs Related to Immune Checkpoint Inhibitor Response: A Systematic Review.
García-Giménez JL; Saadi W; Ortega AL; Lahoz A; Suay G; Carretero J; Pereda J; Fatmi A; Pallardó FV; Mena-Molla S
Int J Mol Sci; 2024 Feb; 25(3):. PubMed ID: 38339019
[TBL] [Abstract][Full Text] [Related]
17. Safety and efficacy of immune checkpoint inhibitors (ICIs) in cancer patients with HIV, hepatitis B, or hepatitis C viral infection.
Shah NJ; Al-Shbool G; Blackburn M; Cook M; Belouali A; Liu SV; Madhavan S; He AR; Atkins MB; Gibney GT; Kim C
J Immunother Cancer; 2019 Dec; 7(1):353. PubMed ID: 31847881
[TBL] [Abstract][Full Text] [Related]
18. Factors affecting tumor responders and predictive biomarkers of toxicities in cancer patients treated with immune checkpoint inhibitors.
Yao L; Jia G; Lu L; Bao Y; Ma W
Int Immunopharmacol; 2020 Aug; 85():106628. PubMed ID: 32474388
[TBL] [Abstract][Full Text] [Related]
19. The Use of Immune Checkpoint Inhibitors in Oncology and the Occurrence of AKI: Where Do We Stand?
Franzin R; Netti GS; Spadaccino F; Porta C; Gesualdo L; Stallone G; Castellano G; Ranieri E
Front Immunol; 2020; 11():574271. PubMed ID: 33162990
[TBL] [Abstract][Full Text] [Related]
20. Concomitant use of analgesics and immune checkpoint inhibitors in non-small cell lung cancer: A pharmacodynamics perspective.
Prasetya RA; Metselaar-Albers M; Engels F
Eur J Pharmacol; 2021 Sep; 906():174284. PubMed ID: 34174268
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
